Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Nasus Pharma Ltd., a foreign private issuer, covers the month of February 2026. The report, dated February 13, 2026, serves to disclose a material corporate event via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial disclosure is the closing of a private placement raising $15.0 million in gross proceeds.
Material Changes
The material change reported is the successful closing of the $15.0 million private placement on February 13, 2026. No comparative financial data or changes in operating metrics versus prior periods are included in this specific filing.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, risk factors, or contingencies beyond the announcement of the capital raise. The document strictly reports the transaction closure.
Investor Verification Checklist
- Verify the final use of proceeds from the $15.0 million private placement.
- Confirm the number of shares issued and the price per share in the private placement.
- Review the full text of the press release (Exhibit 99.1) for details on investor participation.
- Check for any dilution impact on existing shareholders resulting from this issuance.